Regal Rexnord

Phase A — Understand the business

Company Overview

Regal Rexnord Corporation (NYSE: RRX), HQ Milwaukee WI, ~29,200 associates (8,700 US / 8,100 Mexico / 3,600 China / 3,500 India / 4,800 RoW), ~$5,934.5M FY2025 net sales. Three reportable segments:

• Automation & Motion Control (AMC) — $1,689.8M FY2025 (28.5% of sales). Conveyor products, conveying automation subsystems, aerospace components, precision motion control, high-efficiency miniature servo motors, controls/drives/linear actuators, and power management (automatic transfer switches, paralleling switchgear, E-Pods). End markets: discrete factory automation, food & beverage, aerospace, general industrial, medical, data center. This is the secular-growth engine.
• Industrial Powertrain Solutions (IPS) — $2,594.1M FY2025 (43.7%, the largest). Mounted/unmounted bearings, couplings, gearboxes, gear motors, clutches, brakes, and integrated "industrial powertrains" (Regal motor + PT components sold as a sub-system). End markets: general industrial, metals & mining, energy, discrete automation, commercial HVAC. Largely the acquired Rexnord PMC + Altra franchise; ~40% of company sales go through distribution (aftermarket, less cyclical).
• Power Efficiency Solutions (PES) — $1,650.6M FY2025 (27.8%). Fractional-to-~5HP AC/DC motors, variable-speed controls, fans/blowers, air-moving subsystems. Residential & commercial HVAC — seasonal (spring/summer peak), the legacy Regal Beloit motor business.

Corporate history (the roll-up): Regal Beloit merged with the Rexnord Process & Motion Control business (2021) → renamed Regal Rexnord. Acquired Altra Industrial Motion for $5.1B (closed March 2023) — $62/share cash, ~54% premium, debt-financed, the deal that levered the balance sheet. Sold the industrial motors & generators business (Industrial Systems) for $444M (closed April 30 2024) — the pivot away from commodity integral motors toward higher-margin motion/automation.

Customers / contract structure: No single customer >10% of sales in 2023/2024/2025 (low concentration). Mostly purchase-order driven (not take-or-pay); customers can and do cancel/modify POs — a disclosed order-volatility risk. Backlog $2,536.0M at Dec 31 2025 vs $1,707.0M a year earlier (+48.6%), a strong leading indicator inflated by data-center orders.

Strategy: 80/20 (data-driven resource focus), the Regal Rexnord Business System (RBS/Kaizen continuous improvement), raise exposure to secular markets (discrete automation incl. robotics, aerospace, data center, medical), sell integrated "powertrains," deleverage post-Altra, then resume synergistic M&A + buybacks.

Supply Chain

Upstream inputs → RRX → end customer, named:

• Raw materials: steel, copper, aluminum; plus bearings, plastics, electronic assemblies/components, ferrous & non-ferrous castings, and — the chokepoint — rare-earth permanent magnets.
• The single most important chokepoint — rare-earth magnets: China produces ~94% of the world's sintered permanent magnets (up from ~50% two decades ago). RRX's high-efficiency and servo motors depend on them, concentrated in AMC's medical and defense products (its highest-margin lines). RRX disclosed "persistent challenges sourcing rare earth magnets, particularly for products serving the medical and defense markets" as a 2025 AMC organic-growth headwind. The Q2 2025 shortage caused a ~$10M revenue / ~$6M margin hit and a multi-week facility shutdown. Mitigation: dual-sourcing, alternative sourcing, metals hedging.
• Manufacturing footprint: US, Mexico (8,100 associates — key low-cost hub), China, India, Germany, Australia. Flexible footprint used to shift production around tariffs/disruptions. Net PP&E $911.8M: US $386.7M, Mexico $167.3M, Germany $100.2M, China $51.0M.
• Distribution: Large US + Mexico distribution hubs; ~40% of sales through the distributor channel (aftermarket). Two US corporate offices (Milwaukee HQ + Rosemont IL).
• Downstream customers: OEMs (Fortune-100 to small business), distributors, end-users across HVAC, refrigeration, power gen, oil & gas, material handling, aerospace, medical, and hyperscaler/data-center buyers (via power-management/E-Pods). No named 10%+ customer.
• Supplier finance: Bank of America reverse-factoring program, $42.0M outstanding at Dec 31 2025 (in AP) — small, a mild AP-extension lever, not egregious.

Verdict: dual-sourced on most inputs; the un-hedgeable exposure is Chinese rare-earth magnets feeding AMC's premium medical/defense motors — a live, quantified, recurring risk with a specific expiry date (see Lens 10).

Competitive Advantages (moats)

• Scale + scope (the core pitch): RRX claims "unrivaled scale and scope" in power transmission — the breadth to let customers consolidate PT spend onto one vendor (convenience, accountability, lower transaction cost), and >2,000 sales/sales-support associates for go-to-market reach. Genuine but modest: the IPS/AMC markets are "highly fragmented," and scale is a cost/convenience edge, not a monopoly.
• Switching costs / installed base: highly-engineered, application-specific components designed into OEM equipment; large installed base drives like-for-like replacement/aftermarket demand (~40% distributor mix). This is the durable moat — spec-in + aftermarket annuity.
• Integrated "powertrain" solutions: bundling motor + PT components as a sub-system raises stickiness and cross-sell — a differentiation lever competitors with narrow lines can't match. Execution-dependent, not yet a proven moat.
• Data-center power position (emerging moat): switchgear/ATS/E-Pod content for AI data centers is a scarce, spec-heavy capability with a fast-growing order book (Lens 5). Early-innings; not yet a defended franchise.
• Bargaining power: weak-to-moderate. No 10%+ customer (good), but customers are PO-driven and can cancel; upstream, RRX is a price-taker on steel/copper/aluminum and — critically — has little bargaining power over the Chinese rare-earth magnet chokepoint. IP exists but management explicitly says "no one patent or group of patents [is] essential" — the edge is manufacturing/application skill, not a patent wall.

Net: a real but middling industrial moat (installed base + aftermarket + scale/breadth), with an emerging, higher-quality data-center-power vector layered on top. Not a wide-moat compounder; a well-run consolidator.

Segments (revenue, profit, geography, trend)

FY2025 segment P&L:

(Segment EBITDA = GAAP op income + segment amort + deprec. Company-reported adjusted EBITDA $1,307.1M / 22.0% adds back ~$126M restructuring/transaction/integration.)

The single most important analytical reframe: AMC's 7.9% GAAP operating margin is a purchase-accounting artifact, not economics. AMC carries $137.6M and IPS $202.7M of Altra/Rexnord intangible amortization; PES carries only $5.8M. Strip amortization and AMC is a ~19% EBITDA-margin, secular-growth franchise — the crown jewel, not the laggard. GAAP screens make RRX look like a low-margin motor maker; the cash reality is a mid-20s%-EBITDA IPS annuity + a re-accelerating AMC growth engine.

Trend (the story is in the mix shift), Q1 2026 organic:

• AMC +12.1% organic (net sales +15.3% to $457.1M) — "particular strength in data center and discrete automation... signs of recovery in food & beverage." Accelerating hard.
• IPS +2.8% organic ($648.2M) — steady, energy strength vs general-industrial softness.
• PES −10.3% organic ($373.8M) — sharp decline, residential-HVAC destocking / seasonality.
• Consolidated +1.6% organic — pedestrian at the top line; the entire growth story is AMC (and within AMC, data center).

Geography (FY2025): North America $4,160.1M (70.1%), Europe $1,003.0M (16.9%), Asia $442.7M (7.5%), RoW $328.7M (5.5%). By country: US 62.8%, China only 5.3% of sales — RRX's China exposure is a supply problem (magnets), not a demand problem. PES is the most NA-concentrated (78.5%).

Identifiable assets (Dec 31 2025): AMC $4,598.6M, IPS $7,389.1M (holds most of the Rexnord+Altra goodwill/intangibles), PES $1,933.3M.

---

Phase B — Measure performance

Earnings Result (latest print — Q1 2026, reported May 2026)

• Revenue $1,479.1M, +4.3% total / +1.6% organic (FX +2.7%). Modest beat vs consensus.
• Gross profit $549.9M (37.2%, flat YoY).
• GAAP income from operations $152.7M (10.3%, −100bps YoY) — operating income fell even as revenue rose, on mix + investment + tariff/rare-earth cost.
• Interest expense $80.5M vs $90.2M (−10.7%) — the deleveraging tailwind.
• GAAP diluted EPS $0.96 vs $0.86 (+11.6%) — the tell: operating income down, but EPS up double-digits because falling interest expense and a lower tax rate (15.9% vs 21.2%) convert flat operations into EPS growth. This is the mechanical thesis in miniature.
• Adjusted EBITDA margin fell to 20.6%, −~120bps YoY — mix, tariff/price-cost, rare-earth constraints, stepped-up growth investment. Management guided sequential margin improvement across the next 3 quarters, "dollar cost neutrality" in H1 2026, full margin neutrality by year-end.
• Orders/backlog (the bull's exhibit A): Q1 orders +8.5% daily; AMC orders +34% (ex-data-center +28%); aerospace & defense orders +76%, medical +53%, discrete automation +18%; AMC book-to-bill 1.24. Backlog +6.7% sequentially.
• Balance-sheet flags: cash $401.0M (from $521.7M) as AR rebuilt (the securitization boost reverses); OCF only $14.9M in Q1 (−$87.4M YoY) on working-capital/AR — Q1 is seasonally cash-light and the 2025 AR sale is unwinding. Inventory $1,378.4M (up).
• Guidance: company backed FY2026 adjusted EPS $10.20–$11.00 (~10% growth at midpoint) and ~22.5% adj EBITDA margin; FCF guide ~$650M. Note: FY2026 guidance was set below some Street estimates.
• Market reaction: stock has re-rated strongly over the trailing year (below); the tension is "orders exploding / margins compressing now."

FY2025 context (the annual base): revenue $5,934.5M (−1.6%); GAAP diluted EPS $4.20 (+42.9%); adjusted diluted EPS $9.65 (+5.8%); adjusted EBITDA $1,307.1M (22.0% margin, +0.8%). Three-year GAAP EPS: $(0.87) [2023] → $2.94 [2024] → $4.20 [2025]; adjusted EPS: ~$9.12 [2024] → $9.65 [2025] (2024 was a destocking miss vs a $9.75–10.55 original guide).

Earnings Calls (sentiment trend)

Transcripts absent on the research shelf (transcripts=0); grounded in web summaries — label ``.

• Tone has shifted from "deleverage & integrate" (2023–24) to "secular growth & data center" (2025–26). The recurring 2025–26 phrases: data center, E-Pod/switchgear, book-to-bill, orders growth, 80/20, RBS, "margin neutrality."
• Q4 2025 call: orders +53.8%, $735M data-center order wins, "strong orders growth and strategic momentum".
• Q1 2026 call: the balance flips to defending margins — management concedes "margins faced a little more pressure than originally planned," attributes it to mix/tariff/rare-earth/investment, and repeatedly frames a "path to sequential margin improvement." A subtle tonal shift from pure-offense (orders) to offense-plus-reassurance (margin bridge).
• What they stopped emphasizing: the raw leverage/integration-risk narrative of 2023 — replaced by growth. What's new: rare-earth mitigation, tariff price-cost, and (post-April) the CEO succession.

Comps

Multiples , mid-2026 (stockanalysis / GuruFocus / Multiples.vc / company statistics). RRX rows partly from filings + market cap.

Read: RRX sits at the bottom of the peer EV/EBITDA range (~13.4–13.9x), only IR (14.5x) and EMR (15.2x) nearby; ROK/PH/AME cluster 22–28x. The discount is partly deserved — RRX has the highest leverage (~3.3x net vs peers mostly <2x), the lowest organic growth (LSD vs peers), and roll-up amortization depressing GAAP ROE. The bull case (Kerrisdale, Lens 12) is multiple convergence: as leverage falls and data center scales, RRX re-rates toward the automation peer set. The bear case is that the discount is the market correctly pricing a low-growth, leveraged, amortization-heavy consolidator. (Basis: EV ≈ $13.87B mktcap + ~$4.30B net debt ≈ ~$18.2B; ÷ $1,307M adj EBITDA ≈ 13.9x.)

Stock-Price Catalysts (last ~5 years, >5% moves)

`` throughout (macrotrends/company history); 52-week range $127.96–$247.80, last ~$218.19 (Jul 6 2026), +~48% YoY.

• Oct 2022: Altra deal announced — RRX fell on leverage/dilution fears; the overhang that defined 2023–24.
• 2023: GAAP loss year ($(0.87) EPS), heavy integration; stock pressured.
• 2024: industrial destocking + guidance cuts (Q3 2024 cut FY2024 guide) drove the stock to its ~$128 trough — peak pessimism on leverage + soft organic.
• 2025: deleveraging progress + margin expansion + the data-center order narrative ($735M wins) re-rated the stock; roughly doubled off the low.
• 2026 YTD: CEO succession (Aamir Paul named April), Kerrisdale bull report (June), analyst PT hikes (Citi $240, Barclays $245) — momentum, though the stock now sits at/above the ~$210.7 average target.

Pattern: the market trades RRX on (1) leverage/deleveraging trajectory, (2) organic-order momentum (esp. AMC/data center), and (3) guidance credibility. It is not a single-customer or pure-macro name; it re-rates on the leverage-down + secular-up combination and de-rates on guidance cuts.

---

Phase C — Judge people & books

Management

• CEO transition — the headline governance event. Louis V. Pinkham (CEO since April 2019, ex-Crane/Eaton) is stepping down; Aamir Paul (48), President of North America at Schneider Electric, becomes CEO no later than July 1, 2026 (board search launched Oct 2025; Pinkham also leaves the board). Read: hiring a Schneider Electric automation/electrification executive is a deliberate signal that RRX is doubling down on the automation/data-center/electrification story — arguably thesis-confirming. But a fresh CEO at a 66-share, highly-levered roll-up carries real transition risk (strategy reset, a possible "kitchen-sink" quarter, integration-focus dilutionDilutionIssuing new shares, so each existing share owns a smaller slice of the same company.). As of this dossier, Paul is ~1 week into the seat.
• Track record (Pinkham era): executed the transformational roll-up — Rexnord PMC (2021), Altra ($5.1B, 2023), Industrial Systems divestiture ($444M, 2024) — and drove GAAP EPS from a 2023 loss to $4.20, adjusted EPS to $9.65, adj gross margin toward a 40% target, and net leverage down toward ~3.1x. A credible operator; the roll-up is coherent, if not yet fully proven on returns.
• Skin in the game / insider behavior — a yellow flag. Five executives sold ~$12.36M in the trailing 90 days while the stock rose ~35%; CEO Pinkham sold ~$4.76M (May 2026) and ~$7.9M (Feb 2026), and his direct holding fell from ~105.2k shares (June 2025) to ~58.1k. Context softens it (departing CEO diversifying on exit; SAR exercises), but broad C-suite selling into strength is a signal to weigh against the bull narrative.
• Capital allocation: disciplined and legible — debt paydown is priority #1 ($709.4M gross debt repaid in 2025; ~$4.3B net debt → target ~2.0–2.5x, then 1.5x by 2028). Dividend held flat at $1.40/yr ($93M, tiny ~0.6% yield). Buyback authorization $500M with only $145M remaining and $0 repurchased in 2025 — capital is going to the balance sheet, not shareholders, for now. Adjusted ROIC/ROE are improving but GAAP returns remain depressed by the goodwill/amortization load.
• Bench: CFO Robert Rehard (since 2015, ex-Eaton); segment presidents from Eaton/Emerson/Dover/Danaher pedigrees (Kevin Long joined AMC from Dover Aug 2025). Deep industrial operating DNA.
• Archetype: professional managers running a consolidator/roll-up, not founders. Implication: value creation depends on synergy capture + capital allocation + multiple re-rating, not visionary product bets.

Forensic Red Flags

• Receivables securitization — the biggest quality-of-earnings flag. On June 30 2025 RRX launched a $400M AR securitization (PNC/Wells/Truist); at Dec 31 2025 $372.5M of receivables were sold and derecognized, with the $372.5M cash landing in operating cash flow. That is essentially the entire $381.4M YoY jump in 2025 OCF ($990.8M vs $609.4M). The "record 2025 free cash flow" (~$893M = $990.8M OCF − $97.7M capex) is ~$372M inflated by a one-time, non-repeatable AR sale; normalized/clean FCF ≈ ~$520M, consistent with the FY2026 FCFFree cash flowCash left after paying to run and maintain the business. Unlike profit, it is hard to flatter with accounting choices. guide of ~$650M. Not fraud — fully disclosed — but any FCF-yield case must use the clean number. The lever also partially reversed in Q1 2026 (OCF just $14.9M as AR rebuilt).
• Amortization masks GAAP earnings (structural, not deceptive): $346.1M annual intangible amortization from Altra/Rexnord purchase accounting depresses GAAP margins/EPS; adjusted numbers (which the Street uses) add most of it back. Legitimate, but it makes GAAP screens misleading in both directions — cheap on P/CF, expensive on GAAP P/E (~52x).
• Goodwill/intangibles = 72% of assets; tangible book is deeply negative. Goodwill $6,611.3M + intangibles $3,418.4M = $10,029.7M of $13,921.0M total assets; equity $6,853.3M ⇒ tangible book ≈ −$7.2B. Normal for a roll-up, but there's no tangible cushion. Impairment watch: the 2025 goodwill test quantitatively tested 5 reporting units (4 in AMC, 1 in IPS) at 12.5–13.5% discount rates — fair value exceeded carrying for all, but by >10% for only 3 of the 5. Two units (likely AMC) sit on a thin cushion; a growth/margin stumble could trigger a material impairment.
• Working-capital optics: trade receivables fell $842.8M→$524.2M (securitization); inventory rose $1,227.5M→$1,321.7M (a mild build worth watching against soft PES demand). AP includes $42.0M supplier-finance (BofA reverse factoring). None egregious.
• SBC modest: $37.3M (0.6% of sales) — not flattering non-GAAP aggressively.
• Parent-only net loss: the guarantor "Obligor Group" reported a $(192.5)M 2025 net loss (interest sits at the parent; earnings at non-guarantor foreign subs) — structural, not a red flag, but note the structural subordination of senior-note holders to non-guarantor sub liabilities.

Regulatory findings (required sub-section):

• SEC (research-layer): No SEC Litigation Releases and no AAERs naming Regal Rexnord in the 2021-07-10→2026-07-10 window (verified via EDGAR EFTS).
• 10-K Item 3 / Note 12 Contingencies (research-layer): No litigation deemed individually or collectively material to financial position/results/cash flows. Ongoing legacy exposures: (1) a 2007-acquired subsidiary faces numerous claims over sub-fractional motors (made through 2004) in third-party ventilation units alleged to cause fires (CPSC-regulated); an estimated liability is recorded, outcome not predictable; (2) general asbestos, product-liability, warranty, environmental claims in the ordinary course (warranty accrual $30.6M; environmental disclosure threshold $1M, none flagged material).
• Non-SEC enforcement (web): No material FTC/DOJ/FDA/CFPB enforcement, consent decree, or penalty surfaced for Regal Rexnord in 2025–2026 web search.
• Net: clean regulatory/accounting record. The forensic analytical flags (securitization-inflated FCF, thin goodwill cushion, amortization optics) are quality-of-earnings issues, not integrity issues.

---

Phase D — Project & stress-test

Forward Projection (EPS, 3 fiscal years — adjusted diluted)

Bottom-up from FY2025 actual (adj EPS $9.65) + management guidance. All outputs ``; no our model logged (watchlist/unattended rule).

Drivers: consolidated organic ~LSD (AMC double-digit + IPS LSD − PES decline), FX neutral-to-slight, interest expense falling on deleveraging (the biggest EPS lever), margin bridge from 22.0%→22.5%+ adj EBITDA as data center scales and cost actions land, buybacks minimal near-term (cash → debt), share count ~flat ~66–67M.

Base-case forecast (would-be Brier line, not logged): RRX FY2026 adjusted diluted EPS ≥ $10.40, p≈0.62, resolves 2027-02-28. The swing factor is not revenue (backlog covers it) but margin — whether the H2-2026 sequential margin recovery management promised actually shows up against rare-earth/tariff cost. Falsifiable and near-dated.

Bull vs Bear

Bull case. RRX is a mispriced barbell: a stable, ~mid-20s%-EBITDA IPS/aftermarket annuity funding a re-accelerating AMC franchise that is now a genuine AI-data-center power play (switchgear/ATS/E-Pods scaling from ~$120M (2025) to >$900M by 2027, AMC orders +34%, book-to-bill 1.24, backlog +48.6%). On top sits a near-mechanical deleveraging-to-EPS engine — ~$4.3B net debt / ~3.3x falling toward ~1.5x by 2028, converting flat operations into ~10%+ EPS growth as interest expense drops (−12.6% in 2025, −10.7% in Q1). It trades at a wide discount to automation peers (~13.4x EV/EBITDA vs ROK/PH/AME 22–28x). Kerrisdale (June 2026) frames it as an under-the-radar AI-infrastructure name with 100%+ upside on multiple convergence. Extra optionality: 40% gross-margin target, IEEPA-tariff refund (Supreme Court struck the tariffs Feb 20 2026; refund not yet booked), and a Schneider-Electric automation CEO to press the advantage. Contrarian view the market underweights: the boring "motor company" label hides a data-center power franchise whose 2027 revenue is already in backlog, not hoped-for.

Bear case (2–3 permanent-impairment risks). (1) The growth is narrow and low-margin. Consolidated organic is only +1.6%; strip data center and AMC is +28% on a small base while PES falls −10% and IPS crawls — and the incremental data-center/E-Pod mix is compressing margins now (adj EBITDA margin 20.6% in Q1, −120bps). If E-Pods stay low-margin at scale, the "growth" dilutes returns. (2) Rare-earth chokepoint (Lens 10/13) is a recurring, China-controlled hit to AMC's best products, with the export-control "pause" expiring Nov 27 2026. (3) Balance-sheet fragility — 72% goodwill/intangibles, negative tangible book, 2-of-5 reporting units on <10% impairment cushion; a downturn that dents AMC could force a writedown and stall deleveraging. Pre-mortem (18 months out, thesis broke): data-center orders slip/cancel into 2027 (PO-based, not take-or-pay), rare-earth costs re-spike after the Nov-2026 pause lapses, PES stays in decline, the new CEO resets guidance — and a stock that had priced convergence de-rates from ~13.9x back toward ~11x. Are multiples too high? Not vs peers, but vs RRX's own LSD organic growth and 2025's inflated FCF, ~20.6x forward and ~13.9x EV/EBITDA already bake in the recovery — after a double off $128.

Devil's Advocate (short-seller)

Dismantling the bull case:

• Revenue concentration is shifting into a lumpy, PO-cancellable bet. The 2027 story leans on a $735M data-center order book that customers can modify/cancel (RRX's own risk factor). If hyperscaler capex digests or a key buyer reschedules, the "already-in-backlog 2027 revenue" evaporates and the entire re-rating premise cracks.
• The moat is thinner than bulls claim. Management concedes IPS/AMC markets are "highly fragmented" and "no one patent is essential." Switchgear/E-Pods invite entry from much larger electrical players — Eaton, Vertiv, Schneider, ABB, Siemens — precisely the AI-power incumbents. The single most dangerous competitor bulls underrate is Vertiv/Eaton in data-center power, where RRX is a small, late entrant, not an incumbent.
• Quality-of-earnings. 2025 "record FCF" is ~$372M securitization-inflated (Lens 10); GAAP EPS is a fraction of adjusted; tangible book is −$7.2B. The bull deck runs on adjusted EBITDA that adds back $346M of amortization from deals whose returns aren't yet proven.
• Capital-allocation history is unproven on returns. $5.1B for Altra at a 54% premium levered the company to ~4x+ and forced a 3-year deleveraging slog with a frozen dividend and zero buybacks — the "synergy" payoff is still being asserted, not demonstrated in ROIC.
• Insiders are selling into the re-rate ($12.4M/90 days; CEO halved his stake) while the CEO seat changes hands — not the behavior of a team that thinks the stock is about to double.
• What must hold for $218: LSD-plus organic and a data-center ramp to >$900M and margin re-expansion to 22.5%+ and uninterrupted deleveraging and peer-multiple convergence — several independent bets. If 2027 revenue disappoints 20–30% (data center slips), FY2027 adj EPS lands ~$10.5 not ~$12.2, the multiple compresses, and the stock is a ~$150s name — roughly the low end of the analyst range. Single scenario that permanently impairs: a hyperscaler capex air-pocket + a post-Nov-2026 rare-earth re-squeeze hitting AMC simultaneously, forcing a goodwill writedown on the thin-cushion AMC units and re-levering the story.

Management Questions (15, ranked by information value)

1. Of the $735M data-center order book for 2027, how much is firm/non-cancellable PO vs. framework, and what is the customer concentration behind it?
2. What is the gross/EBITDA margin of the switchgear + E-Pod data-center revenue today, and where does it settle at the >$900M 2027 scale — accretive or dilutive to the 22.5% target?
3. Walk through the H2-2026 margin bridge quantitatively: how many bps each from price/cost, rare-earth mitigation, mix, and volume leverage to get from 20.6% (Q1) to the guided ~22.5%?
4. What is your contingency if the China rare-earth export-control pause lapses on Nov 27 2026 — qualified non-China magnet supply as a % of AMC needs, and the cost delta?
5. Aamir Paul — what are the first 2–3 strategic changes you intend, and will the 2026 guidance framework survive the transition intact?
6. At ~1.5x net leverage by 2028, what is the capital-allocation waterfall — buybacks, dividend growth, or a return to M&A — and what deal criteria (size, multiple, synergy) would you accept?
7. How repeatable is 2025's operating cash flow ex the $372.5M receivables securitization, and what is the steady-state FCF conversion?
8. PES organic was −10% in Q1 — how much is destocking/seasonality vs. structural share loss, and when does it inflect?
9. Which reporting units carried <10% goodwill headroom in the 2025 test, and what revenue/margin scenario triggers an impairment?
10. In data-center power you face Eaton, Vertiv, Schneider, ABB — what specifically wins you the socket, and how defensible is it?
11. What is the realistic timing and magnitude of any IEEPA tariff refund, and how are you provisioning for it?
12. Adjusted vs GAAP EPS gap is ~$5.45 (mostly amortization) — when does GAAP ROIC clear your cost of capital?
13. What organic growth does the backlog (+48.6%) actually imply for 2026 revenue, and what's the conversion cadence quarter by quarter?
14. Aerospace/defense orders +76%, medical +53% — how much is rare-earth-shortage catch-up vs. durable demand?
15. What gets RRX to a full investment-grade rating at S&P (from BB+), and what would that do to your cost of capital?

---